Tumour-induced osteomalacia: a literature review and a case report

被引:42
作者
Dadoniene, Jolanta [1 ,2 ,3 ]
Miglinas, Marius [1 ,4 ]
Miltiniene, Dalia [1 ,2 ,3 ]
Vajauskas, Donatas [1 ,5 ]
Seinin, Dmitrij [6 ]
Butenas, Petras [7 ]
Kacergius, Tomas [1 ]
机构
[1] Vilnius State Univ, Fac Med, Vilnius, Lithuania
[2] Vilnius State Univ, Ctr Rheumatol, Vilnius, Lithuania
[3] State Res Inst Innovat Med, Vilnius, Lithuania
[4] Vilnius State Univ, Ctr Nephrol, Vilnius, Lithuania
[5] Vilnius State Univ, Radiol & Nucl Med Ctr, Vilnius, Lithuania
[6] Natl Ctr Pathol, Vilnius, Lithuania
[7] Vilnius Univ Hosp, Santariskiu Klin Orthopaed Traumatol Dept, Vilnius, Lithuania
来源
WORLD JOURNAL OF SURGICAL ONCOLOGY | 2016年 / 14卷
关键词
Tumour-induced osteomalacia; Hypophosphataemia; Fibroblast growth factor 23; PHOSPHATURIC MESENCHYMAL TUMOR; ONCOGENIC HYPOPHOSPHATEMIC OSTEOMALACIA; GROWTH-FACTOR; 23; OCTREOTIDE; DIAGNOSIS; LOCALIZATION; FIBROBLAST-GROWTH-FACTOR-23; SCINTIGRAPHY; MANAGEMENT; RICKETS;
D O I
10.1186/s12957-015-0763-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumour-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterised by severe hypophosphataemia and osteomalacia, with renal phosphate wasting that occurs in association with tumour. The epidemiology likewise aetiology is not known. The clinical presentation of TIO includes bone fractures, bone and muscular pains, and sometimes height and weight loss. TIO may be associated with mesenchymal tumours which may be benign or malignant in rare cases. Mesenchymal tumour itself may be related to fibroblast growth factor 23 (FGF23), which is responsible for hypophosphataemia and phosphaturia occurring in this paraneoplastic syndrome. Hypophosphataemia, phosphaturia and elevated alkaline phosphatase are the main laboratory readings that may lead to more precise investigations and better diagnosis. Finding the tumour can be a major diagnostic challenge and may involve total body magnetic resonance imaging, computed tomography and scintigraphy using radiolabelled somatostatin analogue. The treatment of choice for TIO is resection of a tumour with a wide margin to insure complete tumour removal, as recurrences of these tumours have been reported. We provide here an overview on the current available TIO case reports and review the best practices that may lead to earlier recognition of TIO and the subsequent treatment thereof, even though biochemical background and the long-term prognosis of the disease are not well understood. This review also includes a 4-year-long history of a patient that featured muscular pains, weakness and multiple stress fractures localised in the hips and vertebra with subsequent recovery after tumour resection. Because the occurrence of such a condition is rare, it may take years to correctly diagnose the disease, as is reported in this case report.
引用
收藏
页数:10
相关论文
共 62 条
  • [31] Hu Fang-Ke, 2011, Chin J Cancer, V30, P794, DOI 10.5732/cjc.011.10013
  • [32] TUMOR-INDUCED OSTEOMALACIA: A SINGLE CENTER EXPERIENCE
    Jagtap, Varsha S.
    Sarathi, Vijaya
    Lila, Anurag R.
    Malhotra, Gaurav
    Sankhe, Shilpa S.
    Bandgar, Tushar
    Menon, Padmavathy
    Shah, Nalini S.
    [J]. ENDOCRINE PRACTICE, 2011, 17 (02) : 177 - 184
  • [33] Tumor-induced osteomalacia: An important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature
    Jiang, Yan
    Xia, Wei-bo
    Xing, Xiao-ping
    Silva, Barbara C.
    Li, Mei
    Wang, Ou
    Zhang, Hua-bing
    Li, Fang
    Jing, Hong-li
    Zhong, Ding-rong
    Jin, Jin
    Gao, Peng
    Zhou, Lian
    Qi, Fang
    Yu, Wei
    Bilezikian, John P.
    Meng, Xun-wu
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (09) : 1967 - 1975
  • [34] Determination of the elimination half-life of fibroblast growth factor-23
    Khosravi, Azarmindokht
    Cutler, Carolee M.
    Kelly, Marilyn H.
    Chang, Richard
    Royal, Richard E.
    Sherry, Richard M.
    Wodajo, Felasfa M.
    Fedarko, Neal S.
    Collins, Michael T.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (06) : 2374 - 2377
  • [35] Kinoshita Yuka, 2014, Clin Calcium, V24, P1217, DOI CliCa140812171222
  • [36] Oncogenic Osteomalacia due to FGF23-Expressing Colon Adenocarcinoma
    Leaf, David E.
    Pereira, Renata C.
    Bazari, Hasan
    Jueppner, Harald
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (03) : 887 - 891
  • [37] The Phosphaturic Mesenchymal Tumor: Why is Definitive Diagnosis and Curative Surgery Often Delayed?
    Ledford, Cameron K.
    Zelenski, Nicole A.
    Cardona, Diana M.
    Brigman, Brian E.
    Eward, William C.
    [J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2013, 471 (11) : 3618 - 3625
  • [38] Tumor-induced osteomalacia
    Lewiecki, E. Michael
    Urig, Edward J., Jr.
    Williams, Ralph C., Jr.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (03): : 773 - 777
  • [39] How fibroblast growth factor 23 works
    Liu, Shiguang
    Quarles, L. Darryl
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (06): : 1637 - 1647
  • [40] MCCANCE RA, 1947, Q J MED, V16, P33